PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics


PTC Therapeutics, Inc. (PTCT): $30.58

-0.78 (-2.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PTCT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PTCT POWR Grades


  • PTCT scores best on the Value dimension, with a Value rank ahead of 81.68% of US stocks.
  • PTCT's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • PTCT ranks lowest in Sentiment; there it ranks in the 3rd percentile.

PTCT Stock Summary

  • Ptc Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.88% of US listed stocks.
  • Of note is the ratio of Ptc Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 15.17% of US stocks have a lower such ratio.
  • PTCT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.27% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ptc Therapeutics Inc are PLX, POLY, CCLP, TEN, and CROX.
  • Visit PTCT's SEC page to see the company's official filings. To visit the company's web site, go to www.ptcbio.com.

PTCT Valuation Summary

  • PTCT's EV/EBIT ratio is -12.8; this is 143.69% lower than that of the median Healthcare stock.
  • PTCT's price/earnings ratio has moved down 10.6 over the prior 100 months.
  • PTCT's EV/EBIT ratio has moved down 15.2 over the prior 100 months.

Below are key valuation metrics over time for PTCT.

Stock Date P/S P/B P/E EV/EBIT
PTCT 2021-08-31 6.5 15.7 -7.9 -12.8
PTCT 2021-08-30 6.3 15.1 -7.6 -12.4
PTCT 2021-08-27 6.3 15.2 -7.6 -12.5
PTCT 2021-08-26 6.0 14.4 -7.3 -11.9
PTCT 2021-08-25 6.1 14.6 -7.3 -12.0
PTCT 2021-08-24 6.0 14.4 -7.2 -11.9

PTCT Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 206.95%.
  • Its 2 year cash and equivalents growth rate is now at 26.22%.
  • Its 3 year net income to common stockholders growth rate is now at -4.12%.
Over the past 52 months, PTCT's revenue has gone up $397,040,000.

The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 538.593 -251.332 -523.901
2021-09-30 492.225 -246.858 -454.99
2021-06-30 471.886 -169.009 -391.058
2021-03-31 430.449 -212.674 -454.115
2020-12-31 380.766 -194.071 -438.16
2020-09-30 358.361 -139.911 -441.483

PTCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTCT has a Quality Grade of C, ranking ahead of 45.84% of graded US stocks.
  • PTCT's asset turnover comes in at 0.235 -- ranking 183rd of 682 Pharmaceutical Products stocks.
  • NMTR, ZIOP, and ATXS are the stocks whose asset turnover ratios are most correlated with PTCT.

The table below shows PTCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.235 0.943 -0.271
2021-06-30 0.221 0.945 -0.205
2021-03-31 0.216 0.944 -0.305
2020-12-31 0.205 0.950 -0.360
2020-09-30 0.210 0.951 -0.473
2020-06-30 0.198 0.949 -0.648

PTCT Price Target

For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.58 Average Broker Recommendation 1.77 (Moderate Buy)

PTCT Stock Price Chart Interactive Chart >

Price chart for PTCT

PTCT Price/Volume Stats

Current price $30.58 52-week high $45.80
Prev. close $31.36 52-week low $29.94
Day low $29.94 Volume 540,000
Day high $31.60 Avg. volume 666,941
50-day MA $37.26 Dividend yield N/A
200-day MA $38.62 Market Cap 2.18B

PTC Therapeutics, Inc. (PTCT) Company Bio


PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.


PTCT Latest News Stream


Event/Time News Detail
Loading, please wait...

PTCT Latest Social Stream


Loading social stream, please wait...

View Full PTCT Social Stream

Latest PTCT News From Around the Web

Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2021 Results - Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q4 2021 Earnings Conference Call February 22, 2022, 16:30 ET Company Participants Kylie O'Keefe - VP, Head of Global Strategic Marketing & Business Intelligence Stuart Peltz - Co-Founder & CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Conference Call...

SA Transcripts on Seeking Alpha | February 23, 2022

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:

Yahoo | February 23, 2022

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SOUTH PLAINFIELD, N.J., Feb. 22, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2021. "It is gratifying to see that after two years of investment in the innovation

PR Newswire | February 22, 2022

PTC Therapeutics GAAP EPS of -$2.03 misses by $0.34, revenue of $165.2M beats by $4.12M

PTC Therapeutics press release (NASDAQ:PTCT): Q4 GAAP EPS of -$2.03 misses by $0.34.Revenue of $165.2M (+39.0% Y/Y) beats by $4.12M.

Seeking Alpha | February 22, 2022

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Read More 'PTCT' Stories Here

PTCT Price Returns

1-mo -23.84%
3-mo -15.13%
6-mo -19.65%
1-year -22.88%
3-year -22.52%
5-year 142.89%
YTD -23.22%
2021 -34.74%
2020 27.07%
2019 39.95%
2018 105.76%
2017 52.89%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0363 seconds.